LifeVantage (NasdaqCM:LFVN) Conference December 11, 2025 02:00 PM ET Company ParticipantsCarl Aure - CFONone - OperatorSteve Fife - President and CEONoneWelcome to today's Fireside Chat with LifeVantage Corporation. I'm your host, Doug Lane, Managing Director and Consumer Analyst at Water Tower Research. Today I'm joined by Steve Fife, President and CEO at LifeVantage, and Carl Aure, CFO. So welcome, Steve and Carl.Steve FifeThanks, Doug.Carl AureYeah, thank you, Doug.LifeVantage is a world leader in using ...

SALT LAKE CITY, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer, will participate in the upcoming Water Tower Fireside Chat Series on Thursday, December 11, 2025. The webcast of the fireside chat will begin at approximately 2:00 p.m. Eastern Time on Thur ...

Core Insights - LifeVantage Corporation announced new in vitro study results for its proprietary P84 formula, demonstrating significant biological activity in cellular pathways related to gut regulation, repair, and restoration [1][2] Group 1: Study Findings - The study measured targeted gene expression and protein concentration across four gut cell types, examining 14 gut peptides and proteins that regulate gut health [1] - All 14 peptides were positively influenced, with notable increases such as GRP (gastrin-releasing peptide) showing an increase of 1,087%, TFF3 (trefoil factor 3) increasing by 116%, and VIP (vasoactive intestinal peptide) increasing by 100% [6] - The results exceeded typical biomarker changes of 20-30%, indicating a strong impact of P84 on gut health [2] Group 2: Product Development and Strategy - The next phase of research will involve mRNA sequencing analysis of the P84 blend in combination with other LifeVantage products, including Protandim Nrf2 Synergizer and MindBody GLP-1 System™ [3] - LifeVantage integrated P84 into its product portfolio following the acquisition of LoveBiome, a company focused on gut and microbiome health, in October 2025 [4] - P84 is marketed as part of the Healthy Edge Stack, aimed at enhancing consumer health through cellular activation [4] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can influence gene expression and health [5] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the comprehensive gut activator P84 [5]

Financial Data and Key Metrics Changes - Net revenue for Q1 2026 was $47.6 million, a slight increase of 0.7% from $47.2 million in Q1 2025, reflecting modest growth in consultant numbers and similar growth rates across regions [5][14] - Adjusted EBITDA decreased to $3.9 million, down $500,000 from the previous year, primarily due to lower contribution margins, partially offset by reduced SG&A expenses [5][16] - Gross margin for the quarter was 79.5%, a decrease of 40 basis points compared to the prior year, mainly due to increased shipping and warehouse expenses [15] Business Line Data and Key Metrics Changes - Sales of the MindBody GLP-1 System increased, while sales of Protandim and TrueScience product lines decreased, contributing to the overall revenue changes [14] - The integration of LoveBiome is expected to enhance product offerings and consultant engagement, although it did not contribute to revenue in Q1 2026 as the acquisition closed on October 1, 2025 [22][26] Market Data and Key Metrics Changes - Revenue in Japan increased by 2.6% on a constant currency basis, driven by the launch of the MindBody GLP-1 System [14] - The gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion in 2035, indicating significant market potential for the newly acquired LoveBiome products [6] Company Strategy and Development Direction - The acquisition of LoveBiome positions the company within the rapidly growing gut microbiome health segment, enhancing its product portfolio and market reach [6][12] - The company aims to create a comprehensive wellness ecosystem that addresses various health aspects, including physical and financial wellness, through innovative products and a robust compensation plan [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth trajectory for the remainder of fiscal 2026, anticipating higher revenue in the second half due to seasonal trends and the impact of the LoveBiome acquisition [18][29] - The company is focused on improving operating leverage and profitability metrics, with a target adjusted EBITDA range of $23 million to $26 million for the full year [18] Other Important Information - The company announced a quarterly cash dividend of $0.045 per share, totaling approximately $600,000, to be paid on December 15, 2025 [18] - The company has returned approximately $19.8 million to shareholders through stock repurchases and dividends since the beginning of fiscal 2024 [18] Q&A Session Summary Question: How did the September quarter perform compared to expectations? - Management noted that Q1 is typically a low quarter due to seasonal trends, and the performance was slightly softer than expected but not alarming [21] Question: Was there any revenue impact from LoveBiome before the acquisition closed? - Management confirmed there was zero revenue contribution from LoveBiome prior to the acquisition closing on October 1, 2025 [22] Question: What are the expectations for the second half of the year regarding LoveBiome? - Management indicated that the second half is expected to be larger due to the integration of LoveBiome and the seasonal demand for MindBody products [29]

Core Insights - LifeVantage Corporation reported a revenue of $47.6 million for the first quarter of fiscal 2026, reflecting a 0.7% increase year-over-year [5][10] - The company is focusing on the strategic acquisition of LoveBiome, which positions it as a leader in the natural GLP-1 activation and microbiome health markets [4] - The company expects revenue growth to accelerate in the second half of the fiscal year due to seasonality and the impact of the LoveBiome acquisition [15] Financial Performance - Revenue for the first quarter of fiscal 2026 was $47.6 million, a 0.7% increase from the same period in fiscal 2025 [5][10] - Gross profit was $37.8 million, representing 79.5% of revenue, slightly down from 79.9% in the previous year [6] - Net income for the first quarter was $2.2 million, or $0.17 per diluted share, compared to $1.8 million, or $0.14 per diluted share in the prior year [10][11] Expense Analysis - Commissions and incentives expense increased to $20.7 million, or 43.5% of revenue, up from 43.0% in the previous year [7] - Selling, general and administrative (SG&A) expenses were $14.9 million, or 31.2% of revenue, slightly down from 31.4% in the prior year [8] - Adjusted EBITDA for the first quarter was $3.9 million, compared to $4.4 million in the same period last year [11] Balance Sheet & Liquidity - The company used $2.3 million of cash from operations during the first three months of fiscal 2026, compared to $0.6 million in the same period of fiscal 2025 [12] - Cash and cash equivalents at September 30, 2025, were $13.1 million, down from $20.2 million at June 30, 2025 [12] Shareholder Returns - LifeVantage repurchased 44,000 common shares for approximately $0.6 million during the first quarter [13] - A cash dividend of $0.045 per common share was declared, to be paid on December 15, 2025 [14] Guidance - The company reiterated its revenue guidance for fiscal 2026 in the range of $225 million to $240 million, with adjusted EBITDA expected between $23 million and $26 million [15]

LifeVantage Conference Call Summary Company Overview - **Company Name**: LifeVantage (NasdaqCM: LFVN) - **Industry**: Direct Selling, Nutraceuticals - **Headquarters**: Near Salt Lake City, Utah - **Years in Business**: 16 years - **Active Customers and Consultants**: Approximately 132,000 globally - **Geographic Presence**: Products sold in about 20 countries, with 80% of revenue from North America [2][4] Financial Performance - **Fiscal Year Ended June 30**: - Revenue: $229 million, up 14% year-over-year [3] - EBITDA: Just under $10 million [3] - **Revenue Model**: 70% of revenue is subscription-based, with a 30-day consumption model for products [2][11] - **Balance Sheet**: - Cash: Approximately $20 million - No debt - Working capital: $24 million [15] Product Portfolio - **Core Products**: - Protandim Nrf2: Flagship product, accounts for 50% of revenue, clinically proven to reduce oxidative stress by 40% in 30 days [6] - TrueScience Liquid Collagen: Increases collagen production by 100% [7] - MindBody GLP-1 System: Natural alternative to synthetic drugs, proven to increase GLP-1 production by over 200% [9] - P84 (from LoveBiome acquisition): Focused on gut microbiome [11] - **Market Potential**: - GLP-1 market projected to grow from $19 billion to $88 billion [10] - Gut health market projected to reach $32 billion [11] Strategic Initiatives - **Acquisition**: Acquired LoveBiome to enhance product offerings and geographic reach [5][11] - **Compensation Plan**: Modernized to attract both traditional business builders and micro-influencers, allowing earnings of up to 40% on product sales [12] - **E-commerce Development**: Partnership with Shopify to enhance customer experience [13][17] Growth Opportunities - **Geographic Expansion**: Underrepresented in Europe and Asia, presenting significant growth opportunities [4][20] - **Product Innovation**: Continuous investment in product development and operational efficiencies [14][17] - **Subscription Model**: Provides consistent revenue stream, reducing volatility [20] Shareholder Returns - **Stock Buyback Program**: $60 million plan, with $17 million remaining for future repurchases [18] - **Dividends**: Regular increases in dividend payouts since introduction [19] Market Positioning - **Health Conscious Consumer Base**: Products cater to a growing trend of proactive health management [19][20] - **Competitive Advantage**: Strong foundation with patented, science-backed products supported by clinical studies [22] Conclusion - LifeVantage is positioned for sustained growth through strategic acquisitions, product innovation, and a strong subscription model, while also focusing on expanding its international presence and enhancing its compensation plan to attract new sales representatives [20][22]

Core Insights - LifeVantage Corporation (NASDAQ:LFVN) has completed the acquisition of LoveBiome, enhancing its position in the microbiome health sector [1][3] - The integration of LoveBiome's P84 product with LifeVantage's technologies allows for expansion into the gut health market and strengthens its presence in the U.S., Taiwan, and Europe [2] - Despite recent disappointing quarterly results, the acquisition positions LifeVantage as a leader in the emerging microbiome health sector [3] Company Overview - LifeVantage Corporation is headquartered in Lehi, Utah, and offers advanced nutrigenomic activators, dietary supplements, and skin and hair care products [3] - Core offerings include Protandim, LifeVantage Omega+, and LifeVantage Daily Wellness, reflecting the company's commitment to transforming people's lives [3]

Core Insights - The article discusses the most profitable consumer defensive stocks to consider for investment, emphasizing their resilience in various economic conditions [1][2] - Consumer defensive stocks are characterized by their sustainability, reliability, and lower vulnerability to economic shocks, making them attractive for investors [2] - The consumer staples sector has shown consistent performance, outperforming the MSCI World Index by an average of 5.9% [2] Methodology - A list of profitable consumer defensive stocks was compiled using Finviz stock screener, focusing on those with an EPS growth of over 15% in the last three years and an ROE of at least 5% [4] - Stocks are ranked based on the number of hedge fund holdings, utilizing data from Insider Monkey's Q2 2025 database [4] Hedge Fund Interest - The article highlights the strategy of following hedge fund stock picks, which has historically led to market outperformance, with a reported return of 373.4% since May 2014 [5] Company Highlights - **LifeVantage Corporation (NASDAQ:LFVN)**: Recently completed the acquisition of LoveBiome, enhancing its position in the microbiome health market and expanding its product offerings [6][8] - **Lifeway Foods, Inc. (NASDAQ:LWAY)**: Announced the resignation of a board member and signed a multi-faceted agreement with Danone, which includes appointing new directors and resolving litigation, aimed at improving operational clarity and stability [9][10][11]

Core Insights - LifeVantage Corporation has successfully completed the acquisition of LoveBiome, enhancing its position in the direct sales and gut health market [1][2] - The acquisition allows LifeVantage to expand its product portfolio into the growing microbiome health sector and strengthen its market presence in the US, Taiwan, and Europe [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] - LifeVantage operates through independent consultants who sell products and provide business opportunities to aspiring entrepreneurs [3]

Financial Data and Key Metrics Changes - Revenues increased approximately 13% year over year to $55.1 million, driven largely by the MindBody GLP-1 System [5] - Adjusted EBITDA of $4.8 million was flat versus last year's fourth quarter, with adjusted non-GAAP net income of $2.3 million, or $0.17 per fully diluted share [17][18] - Gross margin expanded by 40 basis points to 79.9% compared to the prior year period, primarily due to lower shipping costs and a favorable product mix [16] Business Line Data and Key Metrics Changes - Revenue in the Americas region increased 14% to $43.5 million, benefiting from the success of the MindBody GLP-1 System [15] - Active accounts in the Americas were up 6%, with increases in both consultants and customers [6] - Revenue in Asia-Pacific/Europe increased by 7.6% to $11.6 million, reflecting the positive impact of the international MindBody rollout [16] Market Data and Key Metrics Changes - The international business returned to growth for the first time in 12 quarters, with revenues in Asia-Pacific/Europe increasing by 8% [5] - The global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a CAGR of 8.4% [7][8] Company Strategy and Development Direction - The company announced a definitive agreement to acquire LoveBiome, which focuses on microbiome health, enhancing its product portfolio and market presence [6][10] - The partnership with LoveBiome aims to accelerate growth through cross-selling opportunities and operational leverage [9][10] - The company is committed to modernizing its technology and marketing stack through a partnership with Shopify to enhance consumer experience [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver sustainable long-term value, supported by the successful rollout of the MindBody GLP-1 System and the LoveBiome acquisition [15] - The outlook for fiscal 2026 anticipates full-year revenue in the range of $225 million to $240 million, with adjusted non-GAAP EBITDA expected between $23 million and $26 million [20] Other Important Information - The company repurchased approximately 160,000 shares during the fourth quarter at an average price of $12.74 per share [19] - A quarterly cash dividend of $0.04 per share was announced, totaling approximately $600,000 [19] Q&A Session Summary Question: What caused the disconnect in fourth quarter revenue expectations? - Management noted that the U.S. experienced some softness due to seasonality impacts, while international numbers remained strong [22][23] Question: How much of the fiscal 2026 growth will come from LoveBiome versus organic growth? - Management indicated that the integration of LoveBiome is still being assessed, with a modest amount of revenue expected from the acquisition [23] Question: Can you provide details on LoveBiome's sales and consultant numbers? - Management refrained from disclosing specific revenue metrics or consultant numbers for LoveBiome at this time [24] Question: What is the market position of LoveBiome? - LoveBiome is a relatively young company, established in 2022, with a focus on gut microbiome health [26][29] Question: How does P84 compare to existing products? - P84 is marketed as a comprehensive product focused on the microbiome, complementing existing prebiotic and probiotic offerings [34]